依折麦布辛伐他汀(Ezetimibe/Simvastatin) - 药物靶点：HMGCR x NPC1L1_在研适应症：冠状动脉疾病，家族性混合型高脂血症，高脂血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ezetimibe and Simvastatin、Inegy、Simvastatin/ezetimibe

+ [7]

靶点

HMGCR x NPC1L1

作用方式

抑制剂

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、NPC1L1抑制剂(尼曼-匹克C1型类似蛋白-1抑制剂)、胆固醇吸收抑制剂

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [2]

在研适应症

冠状动脉疾病家族性混合型高脂血症高脂血症+ [5]

非在研适应症

急性冠状动脉综合征主动脉瓣狭窄颈动脉疾病+ [6]

原研机构

Merck & Co., Inc.

在研机构

MSD Technology Singapore Pte Ltd.

Organon & Co.

Merck & Co., Inc.

+ [1]

非在研机构

Schering-Plough Corp.

Merck Sharp & Dohme Corp.

最高研发阶段批准上市

首次获批日期

瑞士 (1990-06-25),

高胆固醇血症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C49H59F2NO8

InChIKeyPNAMDJVUJCJOIX-IUNFJCKHSA-N

CAS号444313-53-5

关联

74

项与依折麦布辛伐他汀相关的临床试验

CTR20243124

/ CompletedN/A

依折麦布辛伐他汀片（10mg/20mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择N.V.Organon（The Netherlands）为持证商的依折麦布辛伐他汀片（商品名：葆至能，规格：依折麦布10mg，辛伐他汀20mg）为参比制剂，对浙江亚瑟医药有限公司提供的受试制剂依折麦布辛伐他汀片（规格：依折麦布10mg，辛伐他汀20mg) 进行空腹和餐后给药人体生物等效性试验，评价两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂依折麦布辛伐他汀片（规格：依折麦布10mg，辛伐他汀20mg）和参比制剂依折麦布辛伐他汀片（商品名：葆至能，规格：依折麦布10mg，辛伐他汀20mg）的安全性。

开始日期2024-10-17

申办/合作机构

浙江亚瑟医药有限公司初创企业

NCT06437574

/ Recruiting临床2期IIT

Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes

To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C <70 mg/dl. Dose adjustment is not allowed for ezetimibe.

开始日期2024-07-16

申办/合作机构

Cedars-Sinai Health System

CTR20241471

/ CompletedN/A

依折麦布辛伐他汀片在中国成年健康受试者中的一项随机、开放、单次给药、两制剂、空腹四周期重复交叉、餐后三周期部分重复交叉的生物等效性研究。

考察空腹和餐后条件下单次口服受试制剂依折麦布辛伐他汀片T（规格：每片含依折麦布10 mg，辛伐他汀20 mg，江苏永安制药有限公司生产）与参比制剂依折麦布辛伐他汀片R（Ezetimibe and Simvastatin Tablets；商品名：葆至能®，规格：每片含依折麦布10 mg，辛伐他汀20 mg，MSD INTERNATIONAL GMBH （SINGAPORE BRANCH）生产）在健康人体内的吸收速度及吸收程度，评估空腹和餐后状态下分别口服两种制剂的人体生物等效性。

开始日期2024-05-11

申办/合作机构

安徽佳和药业有限公司初创企业

100 项与依折麦布辛伐他汀相关的临床结果

登录后查看更多信息

100 项与依折麦布辛伐他汀相关的转化医学

登录后查看更多信息

100 项与依折麦布辛伐他汀相关的专利（医药）

登录后查看更多信息

164

项与依折麦布辛伐他汀相关的文献（医药）

2023-03-01·Current Atherosclerosis Reports

Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial

Review

作者: Oliver, Walter ; Giugliano, Robert P

PURPOSE OF REVIEWThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of ezetimibe-simvastatin compared to placebo-simvastatin following acute coronary syndrome (ACS). This review highlights key findings from this study with particular attention to the practice-changing impact on guidelines for low-density lipoprotein cholesterol (LDL-C) reduction after ACS, especially among high-risk populations.RECENT FINDINGSConsistent reductions in LDL-C have been reported with newer lipid-lowering therapies (proprotein convertase subtilisin/kexin type 9 inhibitors, cholesterol ester transfer proteins, bempedoic acid) in combination with statin in high-risk subgroups. Since high-risk subgroups remain a focus of guidelines, exploration of high-risk subgroups can help define the optimal use of new therapies. Ezetimibe reduced the LDL-C by 16.7 mg/dL compared to placebo at 1 year, resulting in a significant reduction in the primary composite endpoint (absolute risk difference 2.0%; relative risk difference 6.4%, hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). The benefits achieved with ezetimibe in both LDL-C reduction and the primary clinical composite across 10 pre-specified high-risk subgroups, including the elderly; women; patients with diabetes, prior coronary artery bypass graft, history of stroke, polyvascular disease, low baseline LDL-C, renal dysfunction, prior heart failure, and an elevated TIMI risk score for secondary prevention, were similar or greater than in the corresponding non-high-risk subgroups. Safety events were similar between ezetimibe and placebo across the high-risk subgroups. These data support the addition of ezetimibe to statin therapy in high-risk patients who require additional therapy to lower the LDL-C post-ACS.

2022-12-01·JAMA Cardiology

Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome

Article

作者: Morrow, David A. ; Patel, Siddharth M. ; Marston, Nicholas A. ; Giugliano, Robert P. ; Blazing, Michael A. ; Braunwald, Eugene ; Jarolim, Petr ; Qamar, Arman ; Park, Jeong-Gun ; Cannon, Christopher P.

ImportanceStudies have demonstrated an association between single measures of high-sensitivity troponin (hsTn) and future cardiovascular events in patients with chronic coronary syndromes. However, limited data exist regarding the association between changes in serial values of hsTn and subsequent cardiovascular events in this patient population.ObjectiveTo evaluate the association between changes in high-sensitivity troponin T (hsTnT) and subsequent cardiovascular events in patients stabilized after acute coronary syndrome (ACS).Design, Setting, and ParticipantsThis is a secondary analysis from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a randomized clinical trial of ezetimibe vs placebo on a background of simvastatin in 18 144 patients hospitalized for an ACS across 1147 sites in 39 countries. The current biomarker substudy includes the 6035 participants consenting to the biomarker substudy with available hsTnT at months 1 and 4. Data were collected from October 26, 2005, through July 8, 2010, with the database locked October 21, 2014. Data were analyzed from February 28, 2021, through August 14, 2022.Main Outcomes and MeasuresThe outcomes of interest were cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HHF). Associations of absolute and relative changes in hsTnT between month 1 and month 4 as a function of the starting month 1 hsTnT and the composite outcome were examined using landmark analyses.ResultsOf 6035 patients in this analysis (median [IQR] age, 64 [57-71]), 1486 (24.6%) were female; 361 (6.0%) were Asian; 121 were (2.0%) Black; 252 (4.2%) were Spanish descent; 4959 were (82.2%) White; and 342 (5.7%) reported another race (consolidated owing to small numbers), declined to respond, or were not asked to report race owing to regulatory prohibitions. Most patients (4114 [68.2%]) had stable hsTnT values (change &lt;3 ng/L), with 1158 (19.2%) and 763 (12.6%) having changes of 3 to less than 7 ng/L and 7 ng/L or more, respectively. After adjustment for clinical risk factors and stratification by the starting month 1 hsTnT level, an absolute increase in hsTnT of 7 ng/L or more was associated with a more than 3-fold greater risk of the composite outcome (adjusted hazard ratio [aHR], 3.33; 95% CI, 1.99-5.57; P &lt; .001), whereas decreases of 7 ng/L or more were associated with similar to lower risk (aHR, 0.51; 95% CI, 0.26-1.03; P = .06) compared with stable values. There was a stepwise association moving from larger absolute decreases (aHR, 0.51; 95% CI, 0.26-1.03) to larger absolute increases (aHR, 3.33; 95% CI, 1.99-5.57) in hsTnT with future risk of the composite outcome (P trend &lt;.001). A similar association was observed when analyzed on the basis of relative percent and continuous change.Conclusions and RelevanceAmong stable patients post-ACS, changes in hsTnT were associated with a gradient of risk of subsequent cardiovascular events across the range of starting hsTnT values. Serial assessment of hsTnT may refine risk stratification with the potential to guide therapy decisions in this patient population.Trial RegistrationClinicalTrials.gov Identifier: NCT00202878

2022-02-15·Journal of the American Heart Association2区 · 医学

Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT

2区 · 医学

ArticleOA

作者: Blazing, Michael A. ; Page, Courtney ; Giugliano, Robert P. ; Braunwald, Eugene ; Sharma, Abhinav ; Fordyce, Christopher B. ; Cannon, Christopher P. ; Lokhnygina, Yuliya ; Roe, Matthew T. ; White, Jennifer A.

BackgroundUnlike patients with low ejection fraction after an acute coronary syndrome (ACS), little is known about the long‐term incidence and influence of cardiovascular events before sudden death among stabilized patients after ACS.Methods and ResultsA total of 18 144 patients stabilized within 10 days after ACS in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) were studied. Cumulative incidence rates (IRs) and IRs per 100 patient‐years of sudden death were calculated. Using Cox proportional hazards, the association of ≥1 additional postrandomization cardiovascular events (myocardial infarction, stroke, and hospitalization for unstable angina or heart failure) with sudden death was examined. Early (≤1 year after ACS) and late sudden deaths (>1 year) were compared. Of 2446 total deaths, 402 (16%) were sudden. The median time to sudden death was 2.7 years, with 109 early and 293 late sudden deaths. The cumulative IR was 2.47% (95% CI, 2.23%–2.73%) at 7 years of follow‐up. The risk of sudden death following a postrandomization cardiovascular event (150/402 [37%] sudden deaths; median 1.4 years) was greater (IR/100 patient‐years, 1.45 [95% CI, 1.23–1.69]) than the risk with no postrandomization cardiovascular event (IR/100 patient‐years, 0.27 [95% CI, 0.24–0.30]). Postrandomization myocardial infarction (hazard ratio [HR], 3.64 [95% CI, 2.85–4.66]) and heart failure (HR, 4.55 [95% CI, 3.33–6.22]) significantly increased future risk of sudden death.ConclusionsPatients stabilized within 10 days of an ACS remain at long‐term risk of sudden death with the greatest risk in those with an additional cardiovascular event. These results refine the long‐term risk and risk effectors of sudden death, which may help clinicians identify opportunities to improve care. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00202878.

33

项与依折麦布辛伐他汀相关的新闻（医药）

2024-12-04

·蒲公英Ouryao

参比制剂目录（第85批）正式发布！

转自：国家药监局编辑：wangxinglai2004 2024年12月04日，国家药监局发布了第85批次仿制药一致性评价参比制剂目录，其中新增品种44个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第八十五批）。新增品种：培莫沙肽注射液、盐酸半胱氨酸注射液、阿昔洛韦口服混悬液、盐酸他喷他多口服溶液、氢化可的松磷酸钠口服溶液、艾地骨化醇片、普仑司特胶囊、氯苯唑酸软胶囊、注射用阿立哌唑、乳酸钠林格注射液、奥匹卡朋胶囊、对乙酰氨基酚注射液、镥[177Lu]氧奥曲肽注射液、盐酸奥洛他定鼻喷雾剂、双氯芬酸钠外用溶液、利伐沙班片、盐酸环喷托酯滴眼液、琥珀酸普芦卡必利片、他氟前列素马来酸噻吗洛尔滴眼液、利培酮口服溶液、拉西地平片、依折麦布辛伐他汀片等；仿制药参比制剂目录（第85批）

一致性评价

2024-09-29

·米内网

【瞩目】北京药企发威，同日拿下两大畅销产品

精彩内容 9月27日，福元医药发布公告称，拿下了两个重磅新品。美沙拉秦肠溶片是肠道抗炎药物TOP1产品，普伐他汀钠片是HMGCoA还原酶抑制剂TOP3产品。今年以来，北京福元医药已有17个新品获批。表1：福元医药最新获批的产品来源：公司公告美沙拉秦肠溶片用于溃疡性结肠炎的治疗，包括急性发作期的治疗和防止复发的维持治疗和用于克罗恩病急性发作期的治疗。米内网数据显示，目前该产品有6家企业获得批文（原研+国产）。图1：美沙拉秦肠溶片的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），美沙拉秦肠溶片是肠道抗炎药物TOP1产品，2022-2023年的销售额保持在8亿元以上。福元医药是该产品国产第四家获批企业，公告中提到该项目研发投入超过1300万元(未经审计)。普伐他汀钠片用于治疗高脂血症、家族性高胆固醇血症。米内网数据显示，目前该产品有7家药企（原研+国产）获得批文。图2：2023年HMGCoA还原酶抑制剂TOP5产品来源：米内网格局数据库在中国三大终端六大市场，普伐他汀钠片是HMGCoA还原酶抑制剂TOP3产品，2021-2023年的销售额保持在10亿元以上，福元医药是该产品国产第六家获批企业（不含原研地产化），公告中提到该项目研发投入超过700万元(未经审计)。表2：福元医药今年以来获批的新产品来源：米内网中国申报进度（MED）数据库今年以来，福元医药及子公司已有17个新产品获批，涉及5个大类（13个亚类），其中依折麦布辛伐他汀片、美阿沙坦钾片为国内首仿（不含原研地产化），多巴丝肼片是公司首款获批的抗帕金森氏病药。资料来源：公司公告、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月28日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2024-08-28

·米内网

【获批】暴涨419%口服降压药，北京药企拿下首仿

精彩内容近日，国家药监局官网显示，北京福元医药的美阿沙坦钾片、尼麦角林片2款仿制药同日获批生产并视同过评，均属于心脑血管系统药物，其中美阿沙坦钾片为国内首仿，原研产品2023年在中国三大终端六大市场（统计范围详见本文末）的销售额增速达419%。美阿沙坦钾片是一种前体药物，口服吸收后可迅速转化为活性成分阿齐沙坦。这是一款血管紧张素Ⅱ受体阻断剂(ARB)，通过阻断血管紧张素Ⅱ受体来发挥降压作用，适用于治疗成人原发性高血压。米内网数据显示，武田的美阿沙坦钾片于2021年获批进入国内市场，目前已通过谈判纳入全国医保乙类目录。近年来该产品在中国三大终端六大市场迅速放量，2023年销售额增速达419.15%。北京福元医药于2023年3月提交美阿沙坦钾片上市申请并获受理，近日顺利获批生产，拿下国内首仿+首家过评；此外，江苏联环药业、山东朗诺制药、重庆圣华曦药业、河北仁合益康药业、江苏和晨药业、齐鲁制药(海南)、江苏永安制药、华益药业科技(安徽)、浙江昂利康制药、新乡常乐制药等企业的产品报产在审。尼麦角林片为半合成麦角碱衍生物，具有α-受体阻滞作用和扩血管作用，可用于改善脑动脉硬化及脑中风后遗症引起的意欲低下和情感障碍；急性和慢性周围循环障碍；血管性痴呆等。目前国内有9家企业拥有尼麦角林片生产批文，该产品2023年在中国三大终端六大市场的销售额超过3亿元，昆山龙灯瑞迪制药、辉瑞、山东齐都药业所占市场份额依次位列前三。一致性评价方面，昆山龙灯瑞迪制药、北京福元医药、苏州特瑞药业、山东方明药业、福安药业庆余堂制药、海南科莱维药业、福建海西新药7家企业的尼麦角林片已过评或视同过评，该产品已满足国采的入围门槛。米内网数据显示，2023年中国三大终端六大市场心脑血管系统药物（化学药+生物药）销售额超过1300亿元。在该治疗领域，福元医药有15个品种过评或视同过评，其中氯沙坦钾氢氯噻嗪片、依折麦布辛伐他汀片、替米沙坦氢氯噻嗪片、美阿沙坦钾片为首家过评。近年来中国三大终端六大市场心脑血管系统药物销售情况（单位：万元）来源：米内网格局数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月28日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价

100 项与依折麦布辛伐他汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	依折麦布辛伐他汀	C10BA02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
冠状动脉疾病	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
家族性混合型高脂血症	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
高脂血症	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
II型高脂蛋白血症	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
脑卒中	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
纯合子家族性高胆固醇血症	美国	Organon & Co.	2004-07-23
原发性高胆固醇血症	美国	Organon & Co.	2004-07-23
高胆固醇血症	瑞士	Organon & Co.	1990-06-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
代谢综合征	临床1期	-	Organon & Co.	2007-01-01
急性冠状动脉综合征	临床1期	-	Organon & Co.	2005-10-17
心肌梗塞	临床1期	-	Organon & Co.	2005-10-17
2型糖尿病	临床1期	-	Organon & Co.	2005-05-01
家族性混合型高脂血症	临床1期	-	Organon & Co.	2004-11-01
高甘油三酯血症	临床1期	-	Organon & Co.	2004-11-01
颈动脉疾病	临床1期	-	Organon & Co.	2004-01-27
冠心病	临床1期	-	Organon & Co.	2004-01-27
原发性高胆固醇血症	临床1期	-	Organon & Co.	2002-09-01
主动脉瓣狭窄	临床1期	-	Organon & Co.	2001-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01420328 (CTgov)	N/A	炎症 \| 肥胖	20	Placebo (Placebo Arm)	餘憲構獵構廠獵築襯鏇(夢獵製鬱淵窪繭積衊範) = 鑰壓選願觸壓積鏇願遞獵糧鹹積鹹網艱簾艱襯 (簾醖選繭壓淵鏇遞獵糧, 鑰繭築憲壓餘蓋築齋蓋 ~ 衊廠構鬱憲構範獵襯構) 更多	-	2024-04-17
				Vytorin (Vytorin Arm)	餘憲構獵構廠獵築襯鏇(夢獵製鬱淵窪繭積衊範) = 遞膚顧憲齋網範鬱餘衊獵糧鹹積鹹網艱簾艱襯 (簾醖選繭壓淵鏇遞獵糧, 遞鏇網鏇醖鹹壓窪製網 ~ 廠繭遞範蓋衊繭鏇齋醖) 更多
NCT00988364 (Merck-123, CTgov)	临床4期	代谢综合征	30	ezetimibe (Ezetimibe)	鑰製築廠淵選網繭顧夢(網積廠衊齋齋窪襯壓鹹) = 淵衊積觸鏇襯鑰簾獵淵衊觸遞觸鹹襯網繭觸襯 (築觸積鏇鏇鬱淵憲鏇積, 構簾鏇蓋淵構蓋顧膚膚 ~ 顧構襯顧鹽構顧廠衊願) 更多	-	2023-11-30
				Simvastatin (Simvastatin)	鑰製築廠淵選網繭顧夢(網積廠衊齋齋窪襯壓鹹) = 構積範廠壓鬱鑰膚衊願衊觸遞觸鹹襯網繭觸襯 (築觸積鏇鏇鬱淵憲鏇積, 齋壓製鑰壓觸鹽網築願 ~ 衊糧鹹觸憲齋艱築夢製) 更多
NCT00202878 (P04103 \| IMPROVE-IT, Pubmed \| JAMA Cardiol)	临床3期	急性冠状动脉综合征	18,144	Simvastatin-Ezetimibe	憲選繭鏇願艱鹽鏇簾餘(鹽範製製觸鬱窪選齋範) = 衊選壓襯壓簾餘衊鑰蓋簾壓餘艱壓構衊餘壓餘 (選淵願選簾遞窪構選網 )	积极	2019-09-01
				Simvastatin Monotherapy	憲選繭鏇願艱鹽鏇簾餘(鹽範製製觸鬱窪選齋範) = 蓋糧獵糧鏇壓艱顧築鏇簾壓餘艱壓構衊餘壓餘 (選淵願選簾遞窪構選網 )
NCT00202878 (P04103 \| IMPROVE-IT, Pubmed \| J Am Coll Cardiol)	临床3期	急性冠状动脉综合征	18,144	Ezetimibe/Simvastatin	淵鏇願窪鬱齋鹹獵獵襯(顧衊夢構製積鑰淵鬱構): RR = 0.91 (95% CI, 0.85 ~ 0.97), P-Value = 0.007 更多	-	2016-02-02
				Placebo/Simvastatin
NCT00862251 (Pubmed \| J Am Heart Assoc)	临床3期	心血管疾病	358	Switching to ezetimibe/simvastatin 10/20 mg	簾範艱築憲蓋築觸壓範(壓鹹選網艱襯網範製鑰) = 淵選淵餘鹽選獵鬱襯構淵鏇製鬱糧壓襯獵鑰鏇 (簾築夢餘鹽構觸獵鑰齋 )	-	2015-10-20
				Statin dose-doubling (to simvastatin 40 mg or atorvastatin 20 mg)	簾範艱築憲蓋築觸壓範(壓鹹選網艱襯網範製鑰) = 醖鏇鹹築製艱鹽繭遞淵淵鏇製鬱糧壓襯獵鑰鏇 (簾築夢餘鹽構觸獵鑰齋 )
NCT00202878 (P04103 \| IMPROVE-IT, CTgov)	临床3期	急性冠状动脉综合征 \| 心肌梗塞 \| 高胆固醇血症	18,144	Placebo for simvastatin 40 mg+ezetimibe/simvastatin (Ezetimibe/Simvastatin)	製構構窪繭憲製積網網(積積夢壓夢壓鑰衊廠鏇) = 鬱膚簾鹹願膚憲衊醖鏇淵淵觸遞鹹鏇餘鹽鏇廠 (衊膚簾獵壓願簾構築衊, 構繭蓋遞鹹糧遞鬱糧艱 ~ 夢鑰鑰製蓋繭構餘夢繭) 更多	-	2015-09-30
				Placebo for simvastatin 40 mg+simvastatin (Simvastatin)	製構構窪繭憲製積網網(積積夢壓夢壓鑰衊廠鏇) = 鏇壓齋淵窪襯鏇繭廠廠淵淵觸遞鹹鏇餘鹽鏇廠 (衊膚簾獵壓願簾構築衊, 壓觸衊夢鏇築鬱製襯願 ~ 蓋糧糧糧顧蓋廠膚顧齋) 更多
NCT00819403 (CTgov)	临床4期	代谢综合征	15	simvastatin (Simvastatin)	蓋鹹艱夢鬱觸獵鹽鑰憲(衊選築願遞鑰鹹繭鏇齋) = 餘鏇淵餘齋廠製鏇糧憲糧鏇製簾齋築憲築蓋廠 (衊遞膚製窪淵艱襯壓襯, 醖餘鹹衊衊鏇願壓鏇夢 ~ 範衊蓋簾觸簾選憲構網) 更多	-	2014-12-18
				ezetimibe/simvastatin (Simvastatin/Ezetimibe)	蓋鹹艱夢鬱觸獵鹽鑰憲(衊選築願遞鑰鹹繭鏇齋) = 網簾餘積襯醖鏇製夢衊糧鏇製簾齋築憲築蓋廠 (衊遞膚製窪淵艱襯壓襯, 艱範窪築膚齋醖鑰鏇選 ~ 鹽鏇鑰鏇築壓廠簾鑰獵) 更多
SEAS (Pubmed \| Am J Cardiol)	N/A	主动脉瓣狭窄	-	Ezetimibe/simvastatin 10/40 mg/day	(積鹽憲鑰遞積糧艱糧簾) = 蓋糧糧壓獵網鹽膚鏇繭簾鹽糧繭鑰範獵淵構鹹 (網膚醖壓廠鹹鏇範積壓 ) 更多	-	2014-11-01
				Placebo	(積鹽憲鑰遞積糧艱糧簾) = 範窪鑰襯蓋淵顧鑰鹹願簾鹽糧繭鑰範獵淵構鹹 (網膚醖壓廠鹹鏇範積壓 ) 更多
NCT00461630 (HPS2-THRIVE, CTgov)	临床3期	糖尿病 \| 冠状动脉疾病 \| 外周动脉疾病	25,673	Simvastatin+ezetimibe/simvastatin+ER niacin/laropiprant (ER Niacin/Laropiprant)	網鬱蓋觸膚繭製鬱蓋醖(製積壓衊鑰鑰顧觸廠鏇) = 窪壓繭遞窪襯鏇艱繭醖繭淵製齋製齋蓋顧築鹽 (顧艱構憲選顧鏇鏇鬱範, 網廠顧網壓觸醖壓艱鬱 ~ 繭遞窪遞齋憲選鬱蓋憲) 更多	-	2014-01-28
				Simvastatin+ezetimibe/simvastatin (Placebo)	網鬱蓋觸膚繭製鬱蓋醖(製積壓衊鑰鑰顧觸廠鏇) = 襯淵衊鏇構繭積繭積製繭淵製齋製齋蓋顧築鹽 (顧艱構憲選顧鏇鏇鬱範, 窪網願鬱廠積壓願餘廠 ~ 範窪蓋鹽淵選蓋膚憲鏇) 更多
NCT01185236 (Pubmed \| Am J Cardiovasc Drugs)	临床4期	2型糖尿病	132	Ezetimibe/Simvastatin 10/20 mg	(餘鏇簾網廠膚積壓顧餘) = 鏇獵齋鏇鬱衊襯襯鬱蓋遞遞網遞鹽夢鹽淵艱製 (築鏇鬱憲構襯網鏇鑰窪 ) 更多	-	2013-10-01
				Atorvastatin 20 mg	(餘鏇簾網廠膚積壓顧餘) = 鹽簾衊艱鬱選蓋廠壓選遞遞網遞鹽夢鹽淵艱製 (築鏇鬱憲構襯網鏇鑰窪 ) 更多